Arbutus Biopharma Corporation
ABUS
$4.31
-$0.08-1.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -33.23% | -60.49% | 522.19% | 15.14% | -26.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.23% | -60.49% | 522.19% | 15.14% | -26.62% |
| Cost of Revenue | -43.18% | -59.52% | -64.65% | -41.84% | -49.84% |
| Gross Profit | 45.34% | 59.42% | 137.91% | 48.13% | 53.07% |
| SG&A Expenses | -21.71% | -32.91% | -55.90% | 9.79% | -7.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.70% | -53.10% | -61.79% | -28.60% | -40.34% |
| Operating Income | 36.02% | 52.53% | 108.95% | 32.09% | 41.77% |
| Income Before Tax | 70.03% | 60.73% | 112.74% | -37.21% | 35.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 70.03% | 60.73% | 112.74% | -37.21% | 35.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.03% | 60.73% | 112.74% | -37.21% | 35.11% |
| EBIT | 36.02% | 52.53% | 108.95% | 32.09% | 41.77% |
| EBITDA | 34.28% | 51.67% | 109.15% | 32.56% | 42.39% |
| EPS Basic | 70.50% | 61.27% | 112.54% | -26.33% | 42.32% |
| Normalized Basic EPS | 36.60% | 53.93% | 114.75% | 38.41% | 50.99% |
| EPS Diluted | 70.50% | 61.27% | 109.09% | -26.33% | 42.82% |
| Normalized Diluted EPS | 36.60% | 53.93% | 114.75% | 38.41% | 50.99% |
| Average Basic Shares Outstanding | 1.40% | 1.47% | 1.87% | 8.59% | 12.52% |
| Average Diluted Shares Outstanding | 1.40% | 1.47% | 2.32% | 8.59% | 12.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |